ezogabine has been researched along with morphine in 2 studies
| Studies (ezogabine) | Trials (ezogabine) | Recent Studies (post-2010) (ezogabine) | Studies (morphine) | Trials (morphine) | Recent Studies (post-2010) (morphine) |
|---|---|---|---|---|---|
| 383 | 26 | 241 | 44,270 | 5,200 | 8,695 |
| Protein | Taxonomy | ezogabine (IC50) | morphine (IC50) |
|---|---|---|---|
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.2939 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.2278 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.0828 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0385 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0545 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.122 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1199 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.9308 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.655 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.3305 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.202 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, TK; Ensom, MH; Kiang, TK | 1 |
| Amato, GS; Burns, JF; Eargle, CW; Fritch, PC; Harrison, W; Jones, L; McNaughton-Smith, G; Roeloffs, R; Wickenden, AD | 1 |
1 review(s) available for ezogabine and morphine
| Article | Year |
|---|---|
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic | 2005 |
1 other study(ies) available for ezogabine and morphine
| Article | Year |
|---|---|
Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.
Topics: Adamantane; Animals; Azides; Epilepsy; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Mice; Neuralgia; Structure-Activity Relationship | 2010 |